Status:
RECRUITING
GT201 Injection For The Treatment Of Advanced Solid Tumors
Lead Sponsor:
Grit Biotechnology
Conditions:
Solid Tumor, Adult
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
PHASE2
Brief Summary
Expected to complete 7 to 18 evaluable subjects (patients with advanced solid tumors)，3 dose groups.A modified "3+3" dose-escalation design is utilized,This includes both accelerated dose escalation a...
Eligibility Criteria
Inclusion
- 1\. The Patients (or legally authorized representative) Patients (or legally authorized representative) must have the ability to understand the requirements of the study, have provided written informed consent as evidenced by signature on an informed consent form (ICF) approved by an Institutional Review Board/Independent Ethics Committee (IRB/IEC), must have the ability to understand the requirements of the study;
- Must have a confirmed diagnosis of malignancy of their receptive histologies or cytologies;
- At least one resectable lesion (preferably superficial metastatic lymph nodes) that has not been treated with radiation and has not received other local therapies. The separated tissues ≥1.0cm\^3 (either of single lesion origin or multiple lesions combined) for the preparation of autologous tumor-infiltrating lymphocytes. Minimally invasive treatment where possible.
Exclusion
- The patient who has any active autoimmune disease, history of autoimmune disease, need for systemic steroid hormones or a condition requiring immunosuppressive drug therapy (\>10 mg/day of prednisone or equivalent hormone);
- 2\. Arterial/venous thrombotic events within 3 months prior to enrollment, such as: cerebrovascular accident, deep vein thrombosis and pulmonary embolism occurring;
- 3\. Patients who have refractory or intractable epilepsy, poorly controlled hydrothorax, hydrops abdominis, pericardial effusion or IL-2 contraindications;
- 4\. Participate in other clinical trials within 4 weeks prior to the first dose of this study, or planning to participate in this study and other clinical trials at the same;
- 5\. Patients who have received allogeneic bone marrow transplantation or an organ allograft;
- Patients who have a history of hypersensitivity to any component or excipient of study drugs: autologous tumor infiltrating lymphocytes, cyclophosphamide, fludarabine, IL-2, dimethyl sulfoxide (DMSO), human serum albumin (HSA), dextran-40 and antibiotics (beta lactam antibiotics, gentamicin).
Key Trial Info
Start Date :
September 13 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 13 2026
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT06144671
Start Date
September 13 2023
End Date
September 13 2026
Last Update
December 20 2023
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
The fifth medical center of the General Hospital of the Chinese people's Liberation Army
Beijing, Beijing Municipality, China
2
Union Hospital Tongji Medical College Huazhong University Of Science And Technology
Wuhan, Hubei, China
3
Shandong Cancer Hospital
Jinan, Shandong, China
4
West China Hospital Sichuan University
Chengdu, Sichuan, China, 610000